A rare but potentially debilitating childhood disorder known as PANDAS, short for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections, continues to leave thousands of families navigating a frustrating and often years-long search for answers, as medical recognition, access to specialists, and insurance coverage remain serious barriers to care.
PANDAS was first described in 1998 by researcher Susan Swedo and her colleagues, and it is characterized by the sudden onset of obsessive-compulsive disorder (OCD), tics, or both in children following a Group A Streptococcal (strep) infection.
The condition is believed to occur when a child's immune system misdirects its response against the brain, causing neuroinflammation in regions that control mood, behavior, and movement, according to Channel3000.
Symptoms of PANDAS
Symptoms can appear dramatically, sometimes changing a child's behavior overnight, and may include severe anxiety, emotional outbursts, separation anxiety, cognitive difficulties, sleep problems, and involuntary movements.
The disorder primarily affects children between the ages of 3 and 12, though cases outside this range have been reported. Estimates suggest PANDAS and its broader related condition, PANS (Pediatric Acute-onset Neuropsychiatric Syndrome), affect approximately 1 in 200 children in the United States.
However, the true prevalence may be significantly higher, as recent surveys suggest that as many as 25% of children diagnosed with OCD may actually have PANS or PANDAS.
Despite its impact, obtaining a diagnosis remains a major challenge. There is currently no single definitive test for PANDAS; it is a clinical diagnosis based on a child's symptoms, medical history, and laboratory findings that cannot be explained by any other condition.
Many families report being dismissed or redirected toward psychiatric explanations before receiving a PANDAS diagnosis. Advocacy groups note that more than 30 years after the condition was first identified, too many doctors still express disbelief about its existence.
The situation has grown more complicated following the American Academy of Pediatrics' (AAP) March 2025 Clinical Report on PANS, which several leading PANDAS and PANS organizations are urging be retracted.
Critics argue the report omits key studies supporting proven treatments such as intravenous immunoglobulin (IVIG) and steroids, conflicts with clinical guidelines established by institutions including Stanford, Columbia, and the National Institute of Mental Health (NIMH), and has been misused by insurance providers to deny coverage for essential therapies.
The Alex Manfull Fund, which is named after a 26-year-old man who died from complications of untreated PANDAS following years of misdiagnosis, joined other organizations in a formal rebuttal letter submitted in July 2025, the Alex Manfull Fund reported.
Treatment options for PANDAS typically include antibiotics to address the underlying strep infection, anti-inflammatory medications such as ibuprofen or naproxen, cognitive behavioral therapy (CBT), and, in more severe cases, immunotherapy such as IVIG.
Specialists involved in care can include pediatricians, neurologists, psychiatrists, rheumatologists, and infectious disease doctors, making coordinated, multidisciplinary care essential and often difficult to access.
The PANDAS Physicians Network and other advocacy groups have been working throughout 2025 to educate clinicians, expand access to evidence-based guidelines, and push for earlier identification of the condition.
Researchers are also making incremental strides. New 2025 studies are exploring immune and epigenetic factors in PANS and PANDAS, including the role of inflammatory markers such as IL-17 found in the blood and cerebrospinal fluid of affected children.
Experts emphasize that early diagnosis and prompt treatment are critical; delays can lead to prolonged neuropsychiatric damage and, in the most severe cases, lifelong disability, as per Aspire.
